DxC 500 AU Clinical Chemistry Analyzers: 1. AU w/out ISE, Part No. C63519 2. AU w/ISE, Part No. C63520
原資料は米国FDAの発表(英語)です。商品名・理由は原文のまま表記します。
Beckman Coulter has identified a software issue affecting DxC 500 AU Clinical Analyzers when testing plasma samples. Following user configuration of a Clinical Chemistry test to use units different from the system default, a subsequent configuration change and activation of the draft configuration in the System Configuration page may cause the analyzer to revert the test units to the system default setting without notifying the user. The system does Pre-Review Reminders Include OII and CDRHRecallGroup@fda.hhs.gov in any discussions on change/elevation of recalls to Class I classification and situations involving additional public communications (FDA and/or firm issued). Post-Review Reminders Final Check: Ensure your documentation accurately reflects the final recommendation prior to signature. Complete CTS: Recall Product tab, Additional Recall Event Info, Regulation, and Act. Upload PDFs of Consult, Review Memo, and Classification Letter for Class I Recall in DocMan. [Click to enter extra reminder]To add reminders, type the reminder in the text field to the left then press the Tab key. Doc ID 03534.05.06 2 of 8 not provide a warning or notification to alert the user that the configured units have reverted to the default units. This issue can result in falsely elevated reported results.
| 製造・販売社 | Beckman Coulter Inc. |
|---|---|
| リコール理由 | Beckman Coulter has identified a software issue affecting DxC 500 AU Clinical Analyzers when testing plasma samples. Following user configuration of a Clinical Chemistry test to use units different from the system default, a subsequent configuration change and activation of the draft configuration in the System Configuration page may cause the analyzer to revert the test units to the system default setting without notifying the user. The system does Pre-Review Reminders Include OII and CDRHRecallGroup@fda.hhs.gov in any discussions on change/elevation of recalls to Class I classification and situations involving additional public communications (FDA and/or firm issued). Post-Review Reminders Final Check: Ensure your documentation accurately reflects the final recommendation prior to signature. Complete CTS: Recall Product tab, Additional Recall Event Info, Regulation, and Act. Upload PDFs of Consult, Review Memo, and Classification Letter for Class I Recall in DocMan. [Click to enter extra reminder]To add reminders, type the reminder in the text field to the left then press the Tab key. Doc ID 03534.05.06 2 of 8 not provide a warning or notification to alert the user that the configured units have reverted to the default units. This issue can result in falsely elevated reported results. |
| リスク等級 | Class II (Class II · 中) |
| 進行状況 | Ongoing |
| 報告日 | 2026年10月14日 |
| リコール開始日 | 2026年9月2日 |
| 地域 | CA, United States |
| 流通範囲 | Worldwide - US Nationwide distribution. |
| 数量 | 146 US, 170 OUS |
| コード/ロット | Software version 1.4.5 or earlier. 1. UDI-DI 14987666545058 2. UDI-DI 14987666545065 |
| 区分 | Voluntary: Firm initiated |
| リコール番号 | Z-0084-2027 |
公式出典
U.S. FDA — Recalls, Market Withdrawals & Safety Alerts fda.gov ↗リコール番号でFDA公式サイトから再確認できます。 (リコール番号: Z-0084-2027)
openFDA (U.S. Food & Drug Administration) — food/drug/device enforcement · CC0 1.0 (public domain)
関連情報をさらに探す
上のリンクはリコール番号・商品名で外部検索を開くものであり、検索結果の内容は各サイトの責任です。
このページは米国FDAのデータを整理した生活情報であり、医療アドバイスではありません。正確な内容はFDA公式発表と製造社の案内でご確認ください。